<DOC>
	<DOCNO>NCT02344862</DOCNO>
	<brief_summary>The purpose study exploratory investigation safety efficacy ( dose response optimal dose accord percent reduction baseline serum urate level final visit ) FYU-981 administer orally hyperuricemic patient without gout 8 week ( dose-escalating initial period : 4 week follow maintenance period : 4 week ) method randomize ( dynamic allocation ) , placebo-controlled , double-blind , parallel group comparison .</brief_summary>
	<brief_title>Study FYU-981 Hyperuricemia With Without Gout</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>Hyperuricemic gout patient Serum urate level : &gt; = 7.0mg/dL patient history gout , &gt; = 8.0mg/dL patient hypertension , diabetes metabolic syndrome , &gt; = 9.0mg/dL Gouty arthritis within two week start study treatment Secondary hyperuricemia HbA1c : &gt; = 8.4 % Uric acidoverproduction type classification hyperuricemia History , clinically significant cardiac , hematologic hepatic disease Kidney calculi clinically significant urinary calculus eGFR : &lt; 60mL/min/1.73m^2 Systolic blood pressure : &gt; = 180 mmHg Diastolic blood pressure : &gt; = 110 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>